NEW YORK, November 28, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Quintiles Transnational Holdings Inc. (NYSE: Q), Insys Therapeutics, Inc. (NASDAQ: INSY), HeartWare International, Inc. (NASDAQ: HTWR), Given Imaging Ltd. (NASDAQ: GIVN), and Nektar Therapeutics (NASDAQ: NKTR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Quintiles Transnational Holdings Inc. Research Report
On November 20, 2013, Quintiles Transnational Holdings Inc. (Quintiles) announced that the Vietnam Ministry of Health's Administration of Science, Technology and Training (ASTT) has signed an agreement with the Company to enhance clinical research in Vietnam. Under the two-year agreement, the Company informed that it will collaborate with ASTT to form a larger working group for addressing variety of topics, including improved processes for trial management, development of streamlined processes to improve trial efficiency and quality, and training for investigators and ethics committees. "Quintiles knows how to conduct clinical research to global standards and its experts understand Asia and Vietnam," said Prof. Nguyen Cong Khan, M.D., Ph.D., Director of ASTT. "By sharing their knowledge and insights, Quintiles can help us develop and execute a long-term plan for improving the quality, scope and breadth of clinical research in Vietnam." The Full Research Report on Quintiles Transnational Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Insys Therapeutics, Inc. Research Report
On November 20, 2013, Insys Therapeutics, Inc. (Insys) announced that it is scheduled to present at two upcoming investor conferences: the 25th Annual Piper Jaffray Healthcare Conference taking place on December 3-4, 2013 at The New York Palace, and at the 24th Annual Oppenheimer Healthcare Conference taking place on December 10-11, 2013 at the Crowne Plaza Hotel. The Company informed that its management is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference on December 3, 2013 at 2:30 p.m. EST; and at the 24th Annual Oppenheimer Healthcare Conference on December 10, 2013 at 3:55 p.m. EST. The Full Research Report on Insys Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
HeartWare International, Inc. Research Report
On November 25, 2013, HeartWare International, Inc. (HeartWare) announced that it will be presenting at the 25th Annual Piper Jaffray Healthcare Conference to be held on December 3-4, 2013 at the Palace Hotel in New York City. The Company's CEO, Doug Godshall, is scheduled to present on December 3, 2013 at 2:00 p.m. ET. The Full Research Report on HeartWare International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Given Imaging Ltd. Research Report
On November 11, 2013, Given Imaging Ltd. (Given Imaging) announced that Japan's Central Social Insurance Medical Council (Chuikyo) has approved the recommendation by the Japanese Ministry of Health Labor, and Welfare (MHLW) to provide the reimbursement for the Company's PillCam COLON. Given Imaging stated that with this approval, Chuikyo established a reimbursement of ¥83,100, or approximately $840, per capsule, scheduled to go into effect on January 1, 2014. "We thank the Japanese government for moving so quickly to provide reimbursement for PillCam COLON so that more patients can have access to a safe and effective diagnostic and screening tool for detecting diseases of the colon," said Homi Shamir, President and CEO of Given Imaging. "We are training our team now so that we can maximize this opportunity in 2014." The Full Research Report on Given Imaging Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Nektar Therapeutics Research Report
On November 19, 2013, Nektar Therapeutics (Nektar) reported that the US FDA has accepted the NDA for naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, as announced by Astra Zeneca. The Company also informed that naloxegol is part of the exclusive worldwide license agreement between the Company and AstraZeneca, and was developed using the Company's oral small molecule polymer conjugate technology. The Full Research Report on Nektar Therapeutics - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner